Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
4
result(s) for
"Brett, Peter V., author"
Sort by:
The core
The conclusion of the \"fantasy saga of humans winnowed to the point of extinction by night-stalking demons, and the survivors who fight back\"-- Provided by publisher.
Book
Deep Brain Stimulation
The one-stop resource on deep brain stimulation for functional neurosurgeons! Deep brain stimulation (DBS) is used to modulate dysfunctional circuits in the brain with stimulation pulses applied to specific target areas of the brain. Globally, DBS procedures have been most commonly performed for Parkinson's disease and essential tremor, but there are now new and growing research efforts studying DBS for psychiatric disorders and epilepsy. Deep Brain Stimulation: Techniques and Practices written by the Society for Innovative Neuroscience in Neurosurgery along with Dr. William S. Anderson and distinguished experts presents the latest DBS approaches. The book begins with a history of DBS, general frame-based techniques, patient selection primarily for movement disorders, multidisciplinary collaboration, and ethical considerations. Subsequent chapters detail diverse technologies and disease-specific treatment for Parkinson's disease, essential tremor, dystonia, OCD, epilepsy, major depression, Tourette syndrome, emerging psychiatric indications, and pediatric applications. Key highlights * Lead placement techniques utilizing currently available customized platforms and robotics * Microelectrode recording and image-based direct targeting with MRI and CT to enhance lead placement * Lesioning methods including radiofrequency, and MR-guided focused ultrasound * Discussion of recent innovations in tractography to delineate white matter tracts in the brain and closed loop stimulation DBS has helped thousands of patients with intractable conditions, allowing for a programmable therapy with durable treatment effect. This remarkable guide provides the essentials for functional neurosurgeons to pursue intraoperative research opportunities in this growing subspecialty and incorporate DBS into clinical practice.
eBook
The skull throne
\"Built from the skulls of fallen generals and demon princes, the Skull Throne of Krasia is a seat of honor and powerful magic that keeps the demon corelings at bay. Now it stands empty. From atop it, Ahmann Jardir was meant to conquer the known world, forging a unified army to end the demon war once and for all. Arlen Bales, the Warded Man, stood against this course, challenging Jardir to a duel to the death. Rather than risk defeat, Arlen cast Jardir and himself from a precipice, opening a struggle for succession that threatens to tear the Free Cities of Thesa apart\"--Back cover.
Book
Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: A randomized, dose-escalation phase 1 study in adults
► Recently, a recombinant human IgG1 monoclonal antibody (SII RMab) was developed to replace serum-derived immunoglobulin. ► A randomized dose-escalation phase 1 study along with rabies vaccine was conducted in healthy adults. ► SII RMab was well tolerated with similar reactions to the licensed human rabies immunoglobulin (HRIG). ► The antibody titers in the 10IU/kg cohort were comparable to the vaccine plus HRIG cohort. ► Future post-exposure prophylaxis studies are planned.
Rabies is an essentially fatal disease that is preventable with the timely administration of post-exposure prophylaxis (PEP). The high cost of PEP, which includes vaccine and hyperimmune globulin, is an impediment to the goal of preventing rabies in the developing world. Recently a recombinant human IgG1 anti-rabies monoclonal antibody (SII RMab) has been developed in India to replace serum-derived rabies immunoglobulin. The present study was conducted to demonstrate the safety of SII RMab and to determine the dose resulting in neutralizing serum antibody titers comparable to human rabies immunoglobulin (HRIG) when administered in conjunction with rabies vaccine in a simulated PEP regimen.
This randomized, open label, dose-escalation phase 1 study was conducted in healthy adults at a large tertiary care, referral, public hospital in India. Safety was assessed by active surveillance for adverse events along with standard laboratory evaluations and measurement of anti-drug antibodies (ADA). Anti-rabies antibody levels were measured by rapid fluorescent focus inhibition test (RFFIT) and ELISA. The study duration was 365 days.
SII RMab was well tolerated with similar frequency of local injection site reactions to HRIG. The geometric mean concentrations of rabies neutralizing antibody in the vaccine plus SII RMab 10IU/kg cohort were comparable to the vaccine plus HRIG 20IU/kg cohort throughout the 365-day study period; day 14 geometric mean concentrations 23.4IU/ml (95% CI 14.3, 38.2) vs. 15.3IU/ml (95% CI 7.72, 30.3; p=NS), respectively. Future post-exposure prophylaxis studies of SII RMab at a dose of 10IU/kg in conjunction with vaccine are planned.
Journal Article